**MINUTES**

**CPIC CONFERENCE CALL**

DATE: February 2, 2023

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| CPIC announcements | John McDermott presented that the authors were discussing possible updates to the CPIC mt-RNR1/aminoglycoside guideline to address 2 issues that have arisen: (1) that some aminoglycosides are given topically and may not have been included adequately and (2) that trace amounts of aminoglycosides are added to some vaccines, and some readers had questioned whether that needed to be considered. The topics generated some discussion about possible updates. | CPIC members were encouraged to contact mt-RNR1 guideline authors if they had any further input. |
| Presentation – Role of Patient Advocates and FDA in *DPYD*-Guided Fluoropyrimidine Dosing | Ken Surprenant and Dan Hertz, PharmD, PhD discussed a petition they submitted to the FDA to recommend *DPYD*-guided fluoropyrimidine dosing and the FDA’s response of their petition. A copy of the petition, response from FDA, and presentation slides are included with the minutes. There was substantial discussion by CPIC members. | Those interested in contributing to an additional response to the FDA, or potentially interested in a paper on types of evidence to be considered by regulatory agencies for other gene/drug pairs, were encouraged to contact Dr. Hertz or Kelly. |